# US 2020/0262897 A1 · Dosage and administration of anti-c5 antibodies for treatment of patients with membranoproliferative glomerulonephritis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0262897 A1
- Document ID: US20200262897A1
- Status: Published application
- Kind: A1
- Application number: 16/651,520
- Filed: 2018-10-02
- Published: 2020-08-20
- Earliest claimed: 2017-10-04
- Assignees: Alexion Pharmaceuticals, Inc.
- Applicants: Alexion Pharmaceuticals, Inc.
- Inventors: Giuseppe REMUZZI; Piero RUGGENENTI; Xiang GAO
- Web page: https://patentgrep.com/patent/US20200262897A1

## CPC

- C07K 16/18: against material from animals or humans
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61P 13/12: of the kidneys
- A61K 2039/505: {comprising antibodies}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55: {characterised by the host/recipient, e.g. newborn with maternal antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/565: Complementarity determining region [CDR]
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided are methods for clinical treatment of Membranoproliferative glomerulonephritis (MPGN) by administering an anti-C5 antibody, or antigen binding fragment thereof.

## Claims

### Claim 1

A method of treating an adult human patient with a Membranoproliferative glomerulonephritis (MPGN), the method comprising administering to the patient an anti-C5 antibody, or antigen binding fragment thereof, comprising CDR1, CDR2, and CDR3 heavy chain sequences as set forth in SEQ ID NOs: 1, 2, and 3, respectively, and CDR1, CDR2, and CDR3 light chain sequences as set forth in SEQ ID NOs: 4, 5, and 6, respectively,
wherein the patient has been determined to have biopsy-proven MPGN, creatinine clearance greater than 20 ml/min per 1.73 m2, and/or 24-hour proteinuria exceeding 3.5 g in adults, and
wherein the method comprises an administration cycle comprising (a) an induction phase followed by (b) a maintenance phase, wherein:
(a) the induction phase comprises a period of four weeks, wherein the anti-C5 antibody, or antigen binding fragment thereof, is administered at a dose of 900 mg once per week; and
(b) during the maintenance phase, the anti-C5 antibody, or antigen binding fragment thereof, is administered once at a dose of 1200 mg on the fifth week of the administration cycle, followed by 1200 mg every 14±2 days thereafter.

### Claim 2 (depends on 1)

The method of claim 1, wherein the patient has been determined to have persistently low C3 levels in at least two consecutive evaluations and persistently high sC5b9 levels (>1000 ng/ml) in at least two previous consecutive evaluations.

### Claim 3

A method of treating a pediatric human patient with a Membranoproliferative glomerulonephritis (MPGN), the method comprising administering to the patient an anti-C5 antibody, or antigen binding fragment thereof, comprising CDR1, CDR2, and CDR3 heavy chain sequences as set forth in SEQ ID NOs:1, 2, and 3, respectively, and CDR1, CDR2, and CDR3 light chain sequences as set forth in SEQ ID NOs:4, 5, and 6, respectively,
wherein the patient has been determined to have biopsy-proven MPGN, creatinine clearance greater than 20 ml/min per 1.73 m2, and/or 24-hour proteinuria exceeding 40 mg/h/m2 (or exceeding 2 mg protein/mg creatinine in spot urine samples), and
wherein the method comprises an administration cycle comprising (a) an induction phase followed by (b) a maintenance phase, wherein:
(a) the anti-C5 antibody, or antigen binding fragment thereof, is administered during the induction phase at a dose of:
1. 900 mg once per week for four weeks to a ≥40 kg patient;
2. 600 mg once per week for two weeks to a 30 kg to <40 kg patient;
3. 600 mg once per week for two weeks to a 20 kg to <30 kg patient;
4. 600 mg once per week for one week to a 10 kg to <20 kg patient;
5. 300 mg once per week for one week to a 5 kg to <10 kg patient; and
(b) the anti-C5 antibody, or antigen binding fragment thereof, is administered during the maintenance phase at a dose of:
1. 1200 mg on the fifth week of the administration cycle, followed by 1200 mg every two weeks thereafter, to a ≥40 kg patient;
2. 900 mg on the third week of the administration cycle, followed by 900 mg every two weeks thereafter, to a 30 kg to <40 kg patient;
3. 600 mg on the third week of the administration cycle, followed by 600 mg every two weeks thereafter, to a 20 kg to <30 kg patient;
4. 300 mg on the second week of the administration cycle, followed by 300 mg every two weeks thereafter, to a 10 kg to <20 kg patient; or
5. 300 mg on the second week of the administration cycle, followed by 300 mg every three weeks thereafter, to a 5 kg to <10 kg patient.

### Claim 4 (depends on 3)

The method of claim 3, wherein the patient has been determined to have persistently low C3 levels in at least two consecutive evaluations and persistently high sC5b9 levels (>1000 ng/ml) in at least two previous consecutive evaluations.

### Claim 5 (depends on 1)

The method of claim 1, wherein the anti-C5 antibody, or antigen-binding fragment thereof, comprises:
(a) a heavy chain variable region depicted in SEQ ID NO: 7 and a light chain variable region depicted in SEQ ID NO:8;
(b) a heavy chain variable region depicted in SEQ ID NO: 7, a light chain variable region depicted in SEQ ID NO:8, and a heavy chain constant region depicted in SEQ ID NO:9; or
(c) a heavy chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO:10 and a light chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO:11.

### Claim 6 (depends on 3)

The method of claim 3, wherein the anti-C5 antibody, or antigen-binding fragment thereof, comprises:
(a) a heavy chain variable region depicted in SEQ ID NO: 7 and a light chain variable region depicted in SEQ ID NO:8;
(b) a heavy chain variable region depicted in SEQ ID NO: 7, a light chain variable region depicted in SEQ ID NO:8, and a heavy chain constant region depicted in SEQ ID NO:9; or
(c) a heavy chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO:10 and a light chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO:11.

### Claim 7

(canceled)

### Claim 8 (depends on 1)

The method of claim 1, wherein the anti-C5 antibody, or antigen binding fragment thereof, is administered by intravenous infusion.

### Claim 9 (depends on 3)

The method of claim 3, wherein the anti-C5 antibody, or antigen binding fragment thereof, is administered by intravenous infusion.

### Claim 10 (depends on 1)

The method of claim 1, wherein the anti-C5 antibody, or antigen binding fragment thereof, is administered to an adult human patient by intravenous infusion over a 25 minute to 45 minute period or a period not to exceed two hours.

### Claim 11 (depends on 3)

The method of claim 3, wherein the anti-C5 antibody, or antigen binding fragment thereof, is administered to a pediatric human patient:
(a) aged 12 years to under 18 years by intravenous infusion over a period not to exceed two hours; or
(b) aged less than 12 years old by intravenous infusion over a period not to exceed four hours.

### Claim 12

(canceled)

### Claim 13 (depends on 3)

The method of claim 3, wherein the anti-C5 antibody, or antigen binding fragment thereof, is administered at a dose of:
a) 900 mg once per week for four weeks during the induction phase, 1200 mg on the fifth week of the administration cycle, followed by 1200 mg every two weeks thereafter during the maintenance phase, to a ≥40 kg patient;
b) 600 mg once per week for two weeks during the induction phase, 900 mg on the third week of the administration cycle, followed by 900 mg every two weeks thereafter during the maintenance phase, to a 30 kg to <40 kg patient;
c) 600 mg once per week for two weeks during the induction phase, 600 mg on the third week of the administration cycle, followed by 600 mg every two weeks thereafter during the maintenance phase, to a 20 kg to <30 kg patient;
d) 600 mg once per week for one week during the induction phase, 300 mg on the second week of the administration cycle, followed by 300 mg every two weeks thereafter during the maintenance phase, to a 10 kg to <20 kg patient;
e) 300 mg once per week for one week during the induction phase, 300 mg on the second week of the administration cycle, followed by 300 mg every three weeks thereafter during the maintenance phase, to a 5 kg to <10 kg patient.

### Claim 14 (depends on 1)

The method of claim 1, wherein the anti-C5 antibody, or antigen binding fragment thereof, is administered on a monthly basis after the maintenance phase.

### Claim 15 (depends on 3)

The method of claim 3, wherein the anti-C5 antibody, or antigen binding fragment thereof, is administered on a monthly basis after the maintenance phase.

### Claim 16 (depends on 1)

The method of claim 1, wherein the treatment:
(a) reduces 24 hour proteinuria at week 48 compared to baseline;
(b) results in a complete or partial remission of MPGN;
(c) produces a shift toward normal levels of urinary albumin/creatinine ratio, serum creatinine, creatinine clearance, serum total proteins, serum albumin, LDL, HDL cholesterol and triglycerides levels, hematocrit and/or hemoglobin concentration; and/or
(d) improves one or more renal functional parameters selected from the group consisting of Glomerular Filtration Rate (GFR) (as assessed by Iohexol plasma clearance measurement), Albumin, IgG, sodium, potassium fractional clearance, and renal resistivity index (as assessed by ultrasound evaluation).

### Claim 17 (depends on 3)

The method of claim 3, wherein the treatment:
(a) reduces 24 hour proteinuria at week 48 compared to baseline;
(b) results in a complete or partial remission of MPGN;
(c) produces a shift toward normal levels of urinary albumin/creatinine ratio, serum creatinine, creatinine clearance, serum total proteins, serum albumin, LDL, HDL cholesterol and triglycerides levels, hematocrit and/or hemoglobin concentration; and/or
(d) improves one or more renal functional parameters selected from the group consisting of Glomerular Filtration Rate (GFR) (as assessed by Iohexol plasma clearance measurement), Albumin, IgG, sodium, potassium fractional clearance, and renal resistivity index (as assessed by ultrasound evaluation).

### Claim at position 18

18-19. (canceled)

### Claim 20 (depends on 1)

The method of claim 1, wherein the MPGN is immune-complex-mediated MPGN″ (IC-mediated MPGN) or a C3 glomerulopathy.

### Claim 21 (depends on 3)

The method of claim 3, wherein the MPGN is immune-complex-mediated MPGN″ (IC-mediated MPGN) or a C3 glomerulopathy.

### Claim 22 (depends on 21)

The method of claim 21, wherein the C3 glomerulopathy is dense deposit disease (DDD) or C3 glomerulonephritis.

### Claim 23 (depends on 1)

A kit for treating MPGN in a human patient, the kit comprising: a dose of an anti-C5 antibody, or antigen binding fragment thereof, comprising: CDR1, CDR2, and CDR3 heavy chain sequences as set forth in SEQ ID NOs:1, 2, and 3, respectively, and CDR1, CDR2, and CDR3 light chain sequences as set forth in SEQ ID NOs: 4, 5, and 6, and; and instructions for using the anti-C5 antibody, or antigen binding fragment thereof, in the method of claim 1.

### Claim 24

A method of treating an adult human patient with a Membranoproliferative glomerulonephritis (MPGN), the method comprising administering to the patient an anti-C5 antibody, or antigen binding fragment thereof, comprising CDR1, CDR2, and CDR3 heavy chain sequences as set forth in SEQ ID NOs:19, 18, and 3, respectively, and CDR1, CDR2, and CDR3 light chain sequences as set forth in SEQ ID NOs:4, 5, and 6, respectively,
wherein the patient has been determined to have biopsy-proven MPGN, creatinine clearance greater than 20 ml/min per 1.73 m2, and/or 24-hour proteinuria exceeding 3.5 g, and
wherein the method comprises an administration cycle and, wherein the anti-C5 antibody, or antigen binding fragment thereof, is administered:
(a) once on Day 1 of the administration cycle at a dose of: 2400 mg to a patient weighing ≥40 to <60 kg, 2700 mg to a patient weighing ≥60 to <100 kg, or 3000 mg to a patient weighing ≥100 kg; and
(b) on Day 15 of the administration cycle and every eight weeks thereafter at a dose of 3000 mg to a patient weighing ≥40 to <60 kg, 3300 mg to a patient weighing ≥60 to <100 kg, or 3600 mg to a patient weighing ≥100 kg.

### Claim 25 (depends on 24)

The method of claim 24, wherein the patient has been determined to have persistently low C3 levels in at least two consecutive evaluations and persistently high sC5b9 levels (>1000 ng/ml) in at least two previous consecutive evaluations.

### Claim at position 25

26-28. (canceled)

### Claim 29 (depends on 24)

The method of claim 24, wherein the anti-C5 antibody, or antigen binding fragment thereof, comprises a variant human Fc constant region that binds to human neonatal Fc receptor (FcRn), wherein the variant human Fc CH3 constant region comprises Met-429-Leu and Asn-435-Ser substitutions at residues corresponding to methionine 428 and asparagine 434, each in EU numbering.

### Claim 30 (depends on 24)

The method of claim 24, wherein the anti-C5 antibody, or antigen-binding fragment thereof, comprises:
(a) a heavy chain variable region depicted in SEQ ID NO:12 and a light chain variable region depicted in SEQ ID NO:8;
(b) a heavy chain variable region depicted in SEQ ID NO:12, a light chain variable region depicted in SEQ ID NO:8, and a heavy chain constant region depicted in SEQ ID NO:13 or 9;
(c) a heavy chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO:14 and a light chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO:11; or
(d) a heavy chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO:20 and a light chain polypeptide comprising the amino acid sequence depicted in SEQ ID NO:11.

### Claim at position 28

31-34. (canceled)

### Claim 35 (depends on 24)

The method of claim 24, wherein the anti-C5 antibody, or antigen binding fragment thereof, is administered by intravenous infusion.

### Claim 36 (depends on 24)

The method of claim 24, wherein the anti-C5 antibody, or antigen binding fragment thereof, is administered to an adult human patient by intravenous infusion over a 25 minute to 45 minute period or over a period not to exceed two hours.

### Claim 37

(canceled)

### Claim 38 (depends on 24)

The method of claim 24, wherein the anti-C5 antibody, or antigen binding fragment thereof, is administered on a monthly basis after the maintenance phase.

### Claim at position 33

39-40. (canceled)

### Claim 41 (depends on 24)

The method of claim 24, wherein the treatment results in:
(a) a reduction in 24 hour proteinuria at week 24 or week 48 compared to baseline;
(b) a complete or partial remission of MPGN;
(c) a shift toward normal levels of urinary albumin/creatinine ratio, serum creatinine, creatinine clearance, serum total proteins, serum albumin, LDL, HDL cholesterol and triglycerides levels, hematocrit and/or hemoglobin concentration; and/or
(d) an improvement in one or more renal functional parameters selected from the group consisting of Glomerular Filtration Rate (GFR) (as assessed by Iohexol plasma clearance measurement), Albumin, IgG, sodium, potassium fractional clearance, and renal resistivity index (as assessed by ultrasound evaluation).

### Claim at position 35

42-43. (canceled)

### Claim 44 (depends on 24)

The method of claim 24, wherein the MPGN is immune-complex-mediated MPGN″ (IC-mediated MPGN) or a C3 glomerulopathy.

### Claim 45

(canceled)

### Claim 46 (depends on 44)

The method of claim 44, wherein the C3 glomerulopathy is dense deposit disease (DDD) or C3 glomerulonephritis.

### Claim 47 (depends on 24)

A kit for treating MPGN in a human patient, the kit comprising: a dose of an anti-C5 antibody, or antigen binding fragment thereof, comprising CDR1, CDR2, and CDR3 heavy chain sequences as set forth in SEQ ID NOs:19, 18, and 3, respectively, and CDR1, CDR2, and CDR3 light chain sequences as set forth in SEQ ID NOs:4, 5, and 6; and instructions for using the anti-C5 antibody, or antigen binding fragment thereof, in the method of claim 24.

### Claim 48 (depends on 20)

The method of claim 20, wherein the C3 glomerulopathy is dense deposit disease (DDD) or C3 glomerulonephritis.

### Claim 49 (depends on 3)

A kit for treating MPGN in a human patient, the kit comprising: a dose of an anti-C5 antibody, or antigen binding fragment thereof, comprising: CDR1, CDR2, and CDR3 heavy chain sequences as set forth in SEQ ID NOs:1, 2, and 3, respectively, and CDR1, CDR2, and CDR3 light chain sequences as set forth in SEQ ID NOs: 4, 5, and 6, and; and instructions for using the anti-C5 antibody, or antigen binding fragment thereof, in the method of claim 3.
